1 | Secukinumab 150 mg | [1] Secukinumab Secukinumab | [1] D09967
D09967
| [1] IL17A IL17A 💬 | [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 41 41 |
2 | Secukinumab 150 mg (2 injections per dose | [1] Secukinumab Secukinumab | [1] D09967
D09967
| [1] IL17A IL17A 💬 | [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 269 269 |
3 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | [1] Secukinumab Secukinumab | [1] D09967
D09967
| [1] IL17A IL17A 💬 | [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 |
4 | Secukinumab 150 mg/1 mL Solution for injection | [1] Secukinumab Secukinumab | [1] D09967
D09967
| [1] IL17A IL17A 💬 | [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [2] 37 37, 271 |
5 | Secukinumab 150 mg/ml | [1] Secukinumab Secukinumab | [1] D09967
D09967
| [1] IL17A IL17A 💬 | [6] Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | [1] 271 271 |